President and Chief Executive Officer, Amorsa Therapeutics
Mr. Blanchard has co-founded and has been a member of the leadership teams that helped build several life science companies. Prior to Amorsa, Mr. Blanchard co-founded and served as Chief Operating Officer and Chief Business Officer at Aushon BioSystems, a global provider of protein biomarker detection systems used in drug development and diagnostic applications.
Mr. Blanchard was also an early member of the leadership team for Altus Pharmaceuticals (a spin-out of Vertex Pharmaceuticals and 2006 IPO), where he held several senior management positions. Prior to Altus, he was Director of Sales Operations (The Americas) for Genencor International (2000 IPO; now owned by DuPont), where he led a 40-member commercial team generating over $130 million annually.
Mr. Blanchard was also Senior Vice President, Business Development at Decision Biomarkers and earlier in his career held business unit and sales management positions with Akzo Nobel of the Netherlands and DuPont/Conoco Chemicals. He has an M.B.A and B.S. degree from Miami University.
Jeffrey M. Wiesen, JD
former chair of Mintz Levin’s Life Science practice
Mr. Wiesen is the former President of Mintz Levin and former Chair of the firm’s Life Science practice. He graduated from MIT in 1967 and from Yale Law School in 1971. He spent his entire career at Mintz Levin and has represented biotech companies since 1979, when he represented Biogen in a pioneering collaboration with Schering Plough, involving a substantial equity investment coupled with a three drug research and development collaboration. Mr. Wiesen has successfully led the structuring and negotiation of some of the biotechnology industry’s most successful strategic alliances, venture financings, public offerings and M&A transactions. His clients have ranged from startups to public companies, and he has frequently served as an advisor to their Boards of Directors.
Alex Nivorozhkin, Ph.D.
Chief Operating Officer, Amorsa Therapeutics
Dr. Nivorozhkin is an experienced life science executive with an extensive track record in early technology development. He was a co-founder of both Boston BioCom, LLC, a biopharmaceuticals company funded by the seed investment from Pfizer, and Neo-Advent Technologies LLC, a drug formulation and delivery technologies company. Dr. Nivorozhkin gained substantial experience in the commercial aspects of drug discovery and development at Epix Medical and Inotek Pharmaceuticals where he served as the company’s Head of Medicinal Chemistry. He served as a Senior Program Manager at the Center of Integration of Medicine and Innovative Technologies (CIMIT) at Massachusetts General Hospital, a consortium of the Harvard Medical School-affiliated hospitals, Boston University, Draper Laboratory and MIT. He was also a Scientific Programs Officer at Sheldon and Miriam Adelson Medical Research Foundation.
Dr. Nivorozhkin is a co-inventor of several drug candidates that have advanced to clinical trials, has co-authored over 60 scientific publications in different areas of chemistry, chemical biology, and material sciences and holds more than 20 patents. He received a Ph.D. in Physical Organic Chemistry from Rostov University and conducted his postdoctoral research at the University Paris-Sud, France, and the Department of Chemistry and Chemical Biology, Harvard University.